ACRS Q2 2024 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q2 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$3M+48.0% YoY

Gross Profit

$857,00031.0% margin

Operating Income

-$13M-464.7% margin

Net Income

-$11M-397.2% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+15.3%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$161M

Total Liabilities

$27M

Stockholders' Equity

$134M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+48.0%
Gross Profit	$857,000	$277,000	+209.4%
Operating Income	-$13M	-$32M	+59.6%
Net Income	-$11M	-$30M	+62.8%

Revenue Segments

License and Service

$2M77%

Contract research

$625,00023%